Eye scan math: can two different machines agree on diabetic macular oedema?

NCT ID NCT07816627

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are studying how measurements from two different optical coherence tomography (OCT) machines compare when scanning the back of the eye. The trial includes 338 adults with diabetes and diabetic macular oedema. Participants receive OCT scans on both a Heidelberg Spectralis and a Topcon Triton machine. The goal is to calculate a conversion equation so that measurements from one machine can be understood in terms of the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optical coherence tomography scans using two different machines
What this could lead to
If it works, doctors could compare eye scans from different OCT machines directly, which may make it easier to track diabetic macular oedema over time.
What could go wrong
The study only looks at two specific scanner models, so the equation may not apply to other machines. It also does not test whether using the equation improves patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

338 people

The number who actually took part.

Started

Mar 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of Diabetic Macular Oedema (DMO) as recorded on the Ophthalmology Electronic Medical Record system (Medisoft/Medisight) within Gloucestershire Hospitals NHS Foundation Trust.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or above * Patients with a diagnosis of Type 1 or Type 2 Diabetes Mellitus * Patients with a known diagnosis of DMO in at least one eye * Patients being seen in DMO clinics, Digital Surveillance Clinic or Virtual Diabetic Retinopathy clinics Exclusion Criteria: * Patients under 18 years old * People unwilling or unable to give informed consent * Patients in whom it is not possible to take OCT scans, for instance those with: * Dense cataracts * Corneal Scarring * Severe physical disabilities preventing them from adequate positioning. * People with other ocular pathologies known to impact retinal thickness, including: * Age related Macular Degeneration (AMD) * Branch or central retinal vein occlusion (BRVO/CRVO) * Macular Hole * Glaucoma * High Myopia with a spherical equivalent \> -5.00 diopters * Epiretinal membrane * Eyes with at least one scan containing segmentation errors * Eyes with at least one scan that is ungradable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular oedema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gloucestershire Hospitals NHS Foundation Trust

    Gloucester, Gloucestershire, GL53 7AN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.